Audentes Therapeutics initiated at JPMorgan

Audentes Therapeutics initiated with an Overweight at JPMorgan. JPMorgan analyst Anupam Rama started Audentes Therapeutics with an Overweight rating and $35 price target. The stock has pulled 40% since early October, which represents an attractive long-term entry point, Rama tells investors in a research note. He believes the “de-risked nature” of the known clinical data for gene therapy lead assets AT132 in X-Linked Myotubular Myopathy and AT342 in Crigler-Najjar Syndrome “goes underappreciated” at current share levels.
https://thefly.com/landingPageNews.php?id=2827573